16 results on '"García de la Filia I"'
Search Results
2. DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study
- Author
-
Chaparro, M, primary, Hermida, S, additional, Acosta, D, additional, Fernández-Clotet, A, additional, Barreiro-de Acosta, M, additional, Hernández Martínez, Á, additional, Arroyo, M, additional, Bosca-Watts, M M, additional, Diz-Lois Palomares, M T, additional, Menchén, L, additional, Martínez Cadilla, J, additional, Leo-Carnerero, E, additional, Muñoz Villafranca, C, additional, Sierra-Ausín, M, additional, González, Y, additional, Riestra, S, additional, Sendra Rumbeu, P, additional, Cabello Tapia, M J, additional, García de la Filia, I, additional, Montil Miguel, E, additional, Ceballos, D, additional, Pajares Villarroya, R, additional, Ramírez de la Piscina, P, additional, Martín-Arranz, M D, additional, Ramos, L, additional, Ruiz-Cerulla, A, additional, Teresa de Jesús, M P, additional, San Miguel, E, additional, Calvet, X, additional, Huguet, J M, additional, Keco-Huerga, A, additional, Lorente Poyatos, R H, additional, Muñoz, J F, additional, Ponferrada, Á, additional, Sicilia Aladrén, B, additional, Delgado-Guillena, P, additional, Gómez Delgado, E, additional, Rancel-Medina, F J, additional, Alonso-Galán, H, additional, and Gisbert, J P, additional
- Published
- 2024
- Full Text
- View/download PDF
3. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
- Author
-
García, M J, primary, Riestra, S, additional, Amiot, A, additional, Julsgaard, M, additional, García de la Filia, I, additional, Calafat, M, additional, Aguas, M, additional, de la Peña, L, additional, Roig-Ramos, C, additional, Caballol, B, additional, Casanova, M J, additional, Farkas, K, additional, Boysen, T, additional, Bujanda, L, additional, Cuarán, C, additional, Dobru, D, additional, Fousekis, F, additional, Gargallo-Puyuelo, C J, additional, Savarino, E, additional, Calvet, X, additional, Huguet, J M, additional, Kupcinskas, L, additional, López-Cardona, J, additional, Raine, T, additional, van Oostrom, J, additional, Gisbert, J P, additional, and Chaparro, M, additional
- Published
- 2023
- Full Text
- View/download PDF
4. P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study
- Author
-
Sanz Segura, P, primary, Gomollón, F, additional, García García, S, additional, Vela, M, additional, Fernández-Clotet, A, additional, Muñoz, R, additional, García de la Filia, I, additional, García Prada, M, additional, Ferrer Rosique, J A, additional, García, M J, additional, de Francisco, R, additional, Arias, L, additional, Barrio, J, additional, Guerra, I, additional, Ponferrada Diaz, A, additional, Gisbert, J P, additional, Carrillo-Palau, M, additional, Calvet, X, additional, Márquez-Mosquera, L, additional, Gros, B, additional, Cañete, F, additional, Monfort, D, additional, Madrigal, R E, additional, Roncero, O, additional, Laredo, V, additional, Montoro, M, additional, Muñoz, C, additional, López-Cauce, B, additional, Lorente, R, additional, Fuentes, A, additional, Vega, P, additional, Martín, D, additional, Nerín de la Puerta, J, additional, Varela, P, additional, Casas-Deza, D, additional, Martínez, P, additional, Pajares, R, additional, Lucendo, A J, additional, Domènech, E, additional, and García-López, S, additional
- Published
- 2023
- Full Text
- View/download PDF
5. P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients
- Author
-
Iborra Colomino, M I, primary, Ferreiro-Iglesias, R, additional, Martín-Arranz, M D, additional, Mesonero-Gismero, F, additional, Mínguez, A, additional, Porto Silva, S, additional, García-Ramírez, L, additional, García de la Filia, I, additional, Bastida, G, additional, Nieto García, L, additional, Suárez Ferrer, C, additional, Aguas, M, additional, Barreiro de Acosta, M, additional, and Nos, P, additional
- Published
- 2023
- Full Text
- View/download PDF
6. P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Iborra, M, additional, Sierra, M, additional, Barreiro-de Acosta, M, additional, Fernández-Clotet, A, additional, de Castro, L, additional, Boscá-Watts, M, additional, Casanova, M J, additional, López-García, A, additional, Lorente, R, additional, Rodríguez, C, additional, Carbajo, A Y, additional, Arroyo, M T, additional, Gutiérrez, A, additional, Hinojosa, J, additional, Martínez-Pérez, T, additional, Villoria, A, additional, Bermejo, F, additional, Busquets, D, additional, Camps, B, additional, Cañete, F, additional, Manceñido, N, additional, Monfort, D, additional, Navarro-Llavat, M, additional, Pérez-Calle, J L, additional, Ramos, L, additional, Rivero, M, additional, Angueira, T, additional, Camo, P, additional, Carpio, D, additional, García-de-la-Filia, I, additional, González-Muñoza, C, additional, Hernández, L, additional, Huguet, J M, additional, Morales, V J, additional, Sicilia, B, additional, Vega, P, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
- Author
-
Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, and Gisbert JP
- Abstract
Background: Ustekinumab is approved for ulcerative colitis (UC)., Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice., Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission., Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow-up (median 12 months). Rate of discontinuation was 20% per patient-year of follow-up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1-2.1), steroids at baseline (HR 1.5; 95% CI 1.06-2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09-2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid-free clinical remission. Moderate-severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2-0.5), male sex (OR 0.5; 95% CI 0.4-0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6-0.8) were associated with lower likelihood of steroid-free clinical remission at week 16. One hundred and seventy-six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune-mediated diseases., Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies., (© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
8. Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
- Author
-
Iborra M, Caballol B, Garrido A, Huguet JM, Mesonero F, Ponferrada Á, Arias García L, Boscá Watts MM, Fernández Prada SJ, Brunet Mas E, Gutiérrez Casbas A, Cerrillo E, Ordás I, Ruiz L, García de la Filia I, Escobar Ortiz J, Sicilia B, Ricart E, Domènech E, and Nos P
- Abstract
Background and Aims: Switching from the intravenous to the subcutaneous biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and increase drug levels in patients with Crohn's disease (CD) and ulcerative colitis (UC). The aim of this study was to evaluate long-term outcomes after switching from intravenous IFX (IV-IFX) to SC-IFX, the drug concentration thresholds for maintaining remission and other predictors for loss of response after the switch., Methods: Multicenter observational study involving CD and UC patients who were in clinical remission for at least 24 weeks and scheduled to switch from IV-IFX to SC-IFX., Results: Two hundred and twenty patients were included [74 UC (34%) and 146 (66%) CD]. IV-IFX was administered for 52.5 months [range 25-89]. Pre-switch, 106 (49%) patients were receiving intensified IV-IFX. While SC-IFX levels significantly increased following the switch from IV to SC-IFX, clinical parameters, C-reactive protein and faecal calprotectin remained unchanged during follow-up. SC-IFX levels were significantly higher between patients receiving the standard IV-IFX dose than those with the intensified dose. Immunomodulator therapy at baseline and perianal disease had no effect on IFX trough levels, whereas higher body mass index was associated with increased levels. The suggested optimal SC-IFX cut-off concentration for clinical and biochemical remission based on ROC analysis was 12.2 μg/mL (AUC: 0.62) at week 12 and 13.2 μg/mL (AUC: 0.57) at week 52. Drug persistence was 92% at week 52, with a good safety profile., Conclusion: Switching from IV-IFX to SC-IFX safely maintains long-term remission in patients with CD and UC. In maintenance, the optimal cut-off point associated with remission was 12-13 μg/mL., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
9. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
- Author
-
Sanz Segura P, Gomollón F, Casas D, Iborra M, Vela M, Fernández-Clotet A, Muñoz R, García de la Filia I, García Prada M, Ferrer Rosique JÁ, García MJ, de Francisco R, Arias L, Barrio J, Guerra I, Ponferrada Á, Gisbert JP, Carrillo-Palau M, Calvet X, Márquez-Mosquera L, Gros B, Cañete F, Monfort D, Madrigal Domínguez RE, Roncero Ó, Laredo V, Montoro M, Muñoz C, López-Cauce B, Lorente R, Fuentes Coronel A, Vega P, Martín D, Peña E, Varela P, Olivares S, Pajares R, Lucendo AJ, Sesé E, Botella Mateu B, Nos P, Domènech E, and García-López S
- Abstract
Background: some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible., Aims: to assess the management of antiTNF-IP in IBD, and its impact in both diseases., Methods: patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks., Results: 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse., Conclusion: skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies., Competing Interests: Conflict of interest DCD is partially supported by a Rio-Hortega fellowship from Instituto de Salud Carlos III. IM reports grants and personal fees from MSD, Janssen, Takeda, Kern and Chiesi, during the conduct of the study. AFC has served as a speaker, or has received education funding from Dr. Falk, Janssen, Takeda, Chiesi and Pfizer. MJG has received financial support for travelling and educational activities from Janssen, Pfizer, AbbVie, Takeda, Kern Pharma, Faes Farma and Ferring. IG has served as speaker or has received education funding from Takeda and Tillots. JPG has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. XC reports grants or contracts from Abbvie, Janssen, Kern, Takeda, Galapagos, Lilly, Sandoz; consulting fees from Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Janssen, Takeda, Galapagos, Kern; participation on a Data Safety Monitoring Board or Advisory Board: X Jansen, Galapagos; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Past-president, Societat Catalana de Digestologia. BG has served as advisor to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda, Pfizer and Galapagos. REM reports grants and personal fees from Janssen, Pfizer and Ferring. NP has served as speaker, consultant and advisory board of has received research funding from MSD, Abbvie, Janssen, Takeda, Roche, Sandoz, Ferring, Adacyte, Faes Farma, Kern Pharma, Pfizer, Shire Pharmaceuticals, Vifor Pharma, Chiesi and Tillots. SGL has served as a speaker, advisory member for or has received research funding from AbbVie, MSD, Takeda, Janssen and Pfizer., (Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
- Author
-
García MJ, Riestra S, Amiot A, Julsgaard M, García de la Filia I, Calafat M, Aguas M, de la Peña L, Roig C, Caballol B, Casanova MJ, Farkas K, Boysen T, Bujanda L, Cuarán C, Dobru D, Fousekis F, Gargallo-Puyuelo CJ, Savarino E, Calvet X, Huguet JM, Kupcinskas L, López-Cardona J, Raine T, van Oostrom J, Gisbert JP, and Chaparro M
- Subjects
- Humans, Male, Female, Retrospective Studies, Adult, Middle Aged, Treatment Outcome, Acute Disease, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Severity of Illness Index, Colitis, Ulcerative drug therapy, Colitis, Ulcerative surgery, Infliximab therapeutic use, Infliximab adverse effects, Cyclosporine therapeutic use, Cyclosporine adverse effects, Gastrointestinal Agents therapeutic use, Gastrointestinal Agents adverse effects, Colectomy
- Abstract
Background: The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) and avoid colectomy., Aims: To evaluate the colectomy-free survival and safety of a third-line treatment in patients with ASUC refractory to intravenous steroids and who failed either infliximab or ciclosporin., Methods: Multicentre retrospective cohort study of patients with ASUC refractory to intravenous steroids who had failed infliximab or ciclosporin and received a third-line treatment during the same hospitalisation. Patients who stopped second-line treatment due to disease activity or adverse events (AEs) were eligible. We assessed short-term colectomy-free survival by logistic regression analysis. Kaplan-Meier curves and Cox regression models were used for long-term assessment., Results: Among 78 patients, 32 received infliximab and 46 ciclosporin as second-line rescue treatment. Third-line treatment was infliximab in 45 (58%), ciclosporin in 17 (22%), tofacitinib in 13 (17%) and ustekinumab in 3 (3.8%). Colectomy was performed in 29 patients (37%) during follow-up (median 21 weeks). Of the 78 patients, 32 and 18 were in clinical remission at, respectively, 12 and 52 weeks. At the last visit, 25 patients were still on third-line rescue treatment, while 12 had stopped it due to clinical remission. AEs were reported in 26 (33%) patients. Two patients died (2.6%), including one following colectomy., Conclusion: Third-line rescue treatment avoided colectomy in over half of the patients with ASUC and may be considered a therapeutic strategy., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
11. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry.
- Author
-
Casas Deza D, Polo Cuadro C, de Francisco R, Vela González M, Bermejo F, Blanco I, de la Serna Á, Bujanda L, Bernal L, Rueda García JL, Gargallo-Puyuelo CJ, Fuentes-Valenzuela E, Castro B, Guardiola J, Ladrón G, Suria C, Sáez Fuster J, Gisbert JP, Sicilia B, Gomez R, Muñoz Vilafranca C, Barreiro-De Acosta M, Peña E, Castillo Pradillo M, Cerrillo E, Calvet X, Manceñido N, Monfort I Miquel D, Marín S, Roig C, Marce A, Ramírez de Piscina P, Betoré E, Martin-Cardona A, Teller M, Alonso Abreu I, Maroto N, Frago S, Gardeazabal D, Pérez-Martínez I, Febles González ÁD, Barrero S, Taxonera C, García de la Filia I, Ezkurra-Altuna A, Madero L, Martín-Arranz MD, Gomollón F, Domènech E, and García-López S
- Subjects
- Humans, Male, Female, Adult, Spain, Middle Aged, Secondary Prevention methods, Crohn Disease complications, Abdominal Abscess etiology, Abdominal Abscess prevention & control, Abdominal Abscess therapy, Drainage methods, Registries, Anti-Bacterial Agents therapeutic use, Recurrence
- Abstract
Introduction: Intra-abdominal abscesses complicating Crohn's disease [CD] are a challenging situation. Their management, during hospitalisation and after resolution, is still unclear., Methods: Adult patients with CD complicated with intra-abdominal abscess. who required hospitalisation, were included from the prospectively maintained ENEIDA registry from GETECCU. Initial strategy effectiveness and safety to resolve abscess was assessed. Survival analysis was performed to evaluate recurrence risk. Predictive factors associated with resolution were evaluated by multivariate regression and predictive factors associated with recurrence were assessed by Cox regression., Results: In all, 520 patients from 37 Spanish hospitals were included; 322 [63%] were initially treated with antibiotics alone, 128 [26%] with percutaneous drainage, and 54 [17%] with surgical drainage. The size of the abscess was critical to the effectiveness of each treatment. In abscesses < 30 mm, the antibiotic was as effective as percutaneous or surgical drainage. However, in larger abscesses, percutaneous or surgical drainage was superior. In abscesses > 50 mm, surgery was superior to percutaneous drainage, although it was associated with a higher complication rate. After abscess resolution, luminal resection was associated with a lower 1-year abscess recurrence risk [HR 0.43, 95% CI 0.24-0.76]. However, those patients who initiated anti-TNF therapy had a similar recurrence risk whether luminal resection had been performed., Conclusions: Small abscesses [<30mm] can be managed with antibiotics alone; larger ones require drainage. Percutaneous drainage will be effective and safer than surgery in many cases. After discharge, anti-TNF therapy reduces abscess recurrence risk in a similar way to bowel resection., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
12. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
- Author
-
Iborra M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, Mínguez A, Porto-Silva S, García-Ramírez L, García de la Filia I, Aguas M, Nieto-García L, Suárez Ferrer C, Bastida G, Barreiro-De-Acosta M, and Nos P
- Subjects
- Humans, Tumor Necrosis Factor Inhibitors therapeutic use, Treatment Outcome, Remission Induction, C-Reactive Protein, Ustekinumab therapeutic use, Colitis, Ulcerative surgery
- Abstract
Objective: Ustekinumab was recently approved for the treatment of moderate-to-severe ulcerative colitis (UC). Although data from the UNIFI clinical trial are encouraging, real-world data assessing effectiveness and safety are scarce. The aim of this study was to assess the effectiveness, safety and pharmacokinetics of ustekinumab in a large cohort of refractory UC patients., Methods: Multicenter observational study of UC patients who received ustekinumab for active disease. The Partial Mayo Score (PMS), endoscopic activity, C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at different time points. Demographic and clinical data, adverse events (AEs) and surgeries were documented., Results: A total of 108 patients were analyzed from 4 referral Spanish hospitals. The clinical remission rates were 59%, 56.5%, 57% and 69% of patients at weeks 8, 16, 24 and 52, respectively. Normalization of FC was achieved in 39.6%, 41% and 51% at weeks 8, 24 and 52, respectively. CRP normalization was observed in 79%, 75% and 76.5% of patients at weeks 8, 24 and 52, respectively. Fewer previous anti-TNF agents and loss of response to anti-TNF were associated with clinical response and normalization of FC, respectively. AEs were observed in 5 patients, and 9 underwent colectomy. Ustekinumab persistence rates were 91%, 83% and 81% at 24, 48 and 96 weeks, respectively., Conclusions: Ustekinumab demonstrated, in the real-world setting, long-term effectiveness and a favorable safety profile in a cohort of refractory UC patients.
- Published
- 2024
- Full Text
- View/download PDF
13. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
- Author
-
Chaparro M, Garre A, Iborra M, Sierra-Ausín M, Barreiro-de Acosta M, Fernández-Clotet A, de Castro L, Boscá-Watts M, Casanova MJ, López-García A, Lorente R, Rodríguez C, Carbajo AY, Arroyo MT, Gutiérrez A, Hinojosa J, Martínez-Pérez T, Villoria A, Bermejo F, Busquets D, Camps B, Cañete F, Manceñido N, Monfort D, Navarro-Llavat M, Pérez-Calle JL, Ramos L, Rivero M, Angueira T, Camo Monterde P, Carpio D, García-de-la-Filia I, González-Muñoza C, Hernández L, Huguet JM, Morales VJ, Sicilia B, Vega P, Vera I, Zabana Y, Nos P, Suárez Álvarez P, Calviño-Suárez C, Ricart E, Hernández V, Mínguez M, Márquez L, Hervías Cruz D, Rubio Iturria S, Barrio J, Gargallo-Puyuelo C, Francés R, Hinojosa E, Del Moral M, Calvet X, Algaba A, Aldeguer X, Guardiola J, Mañosa M, Pajares R, Piqueras M, García-Bosch O, López Serrano P, Castro B, Lucendo AJ, Montoro M, Castro Ortiz E, Mesonero F, García-Planella E, Fuentes DA, Bort I, Delgado-Guillena P, Arias L, Iglesias A, Calvo M, Esteve M, Domènech E, and Gisbert JP
- Subjects
- Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Registries, Remission Induction, Ustekinumab administration & dosage, Colitis, Ulcerative drug therapy, Ustekinumab therapeutic use
- Abstract
Background and Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life., Methods: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16., Results: A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% of patients in remission]. In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at Weeks 24 and 52, respectively; 36% of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at Week 16, 63% at Week 56, and 59% at Week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection., Conclusions: Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
14. Pneumatosis intestinalis in Crohn's disease.
- Author
-
González-Olivares C, Palomera-Rico A, Romera-Pintor Blanca N, Sánchez-Aldehuelo R, Figueroa-Tubío A, García de la Filia I, and López-Sanromán A
- Subjects
- Conservative Treatment, Crohn Disease diagnostic imaging, Crohn Disease therapy, Female, Humans, Middle Aged, Pneumatosis Cystoides Intestinalis diagnostic imaging, Crohn Disease complications, Pneumatosis Cystoides Intestinalis etiology
- Published
- 2019
- Full Text
- View/download PDF
15. Nakamura polyp: An unusual endoscopic finding.
- Author
-
Sánchez-Aldehuelo R, Figueroa-Tubío A, García de la Filia I, González-Olivares C, García García de Paredes A, García-Cosío M, Vázquez-Sequeiros E, and Albillos A
- Subjects
- Aged, Colonic Polyps complications, Colonic Polyps pathology, Colonic Polyps surgery, Gastrointestinal Hemorrhage etiology, Humans, Inflammation, Male, Occult Blood, Colonic Polyps diagnostic imaging, Colonoscopy
- Published
- 2019
- Full Text
- View/download PDF
16. Recurrent gastrointestinal bleeding secondary to Dieulafoy's lesion successfully treated with endoscopic ultrasound-guided sclerosis.
- Author
-
García de la Filia I, Hernanz N, Vázquez Sequeiros E, and Tavío Hernández E
- Subjects
- Aged, 80 and over, Arterioles diagnostic imaging, Arterioles pathology, Epinephrine administration & dosage, Gastrointestinal Hemorrhage etiology, Hemostasis, Endoscopic instrumentation, Humans, Injections, Intralesional, Male, Polidocanol administration & dosage, Recurrence, Sclerosing Solutions administration & dosage, Arterioles drug effects, Endosonography methods, Epinephrine therapeutic use, Gastric Fundus blood supply, Gastrointestinal Hemorrhage therapy, Gastroscopy methods, Hemostasis, Endoscopic methods, Polidocanol therapeutic use, Sclerosing Solutions therapeutic use, Sclerotherapy methods
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.